Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results

Oculis (NASDAQ:OCS) announced its quarterly earnings data on Tuesday. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.10, Zacks reports. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.26 million.

Oculis Price Performance

OCS stock traded down $0.52 during trading on Wednesday, hitting $7.11. The stock had a trading volume of 85,198 shares, compared to its average volume of 418,116. The company’s 50 day moving average price is $9.53 and its two-hundred day moving average price is $18.62. Oculis has a 1-year low of $7.11 and a 1-year high of $34.47. The stock has a market cap of $412.06 million, a price-to-earnings ratio of -4.11 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35.

Analyst Ratings Changes

Several brokerages have recently weighed in on OCS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Thursday, October 15th. HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of Oculis in a research report on Wednesday, October 21st. Guggenheim dropped their price objective on shares of Oculis to $40.00 and set a “buy” rating for the company in a research note on Wednesday. Wall Street Zen upgraded Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, JPMorgan Chase & Co. cut their price objective on Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Friday, August 14th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $38.89.

Oculis Company Profile

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.